- Ublituximab (Briumvi®) has been listed on the PBS for adults with relapsing remitting MS
- Ublituximab is a new anti-CD20 monoclonal antibody therapy targeting B cells in MS.
- With twice-yearly dosing after the first dose and a one-hour infusion time, this provides another treatment option for people with relapsing remitting MS
The Federal Government announced on 8 Jan 2026 that ublituximab (Briumvi®) has been listed on the Pharmaceutical Benefits Scheme (PBS) for adults with relapsing remitting MS.
In June 2025, ublituximab was approved by the Therapeutic Goods Administration (TGA) for treating adults with relapsing forms of MS. It was recommended for listing on the PBS for adults with relapsing remitting MS by the Pharmaceutical Benefits Advisory Committee (PBAC) in May 2025.
The PBAC considers many factors when making recommendations. These include the effectiveness and cost of a treatment relative to other available medicines and the cost of a new listing to the government. Once a medication receives a positive recommendation from the PBAC, it is submitted to the Federal Government for final approval.
MS Australia strongly advocated to the PBAC for ublituximab to be listed on the PBS in our submission here.
How does ublituximab work and what do clinical trials show?
Ublituximab is a monoclonal antibody treatment that is delivered intravenously (into the vein). It targets B cells (a type of immune cell) that produce a protein called CD20 and reduces their number. This, in turn, reduces the number of relapses, disability progression and the number of new lesions.
Recent phase 3 clinical trials showed ublituximab is an effective treatment, reducing the frequency of relapses and new MRI lesions in people with MS compared to the oral treatment teriflunomide.
Ublituximab has also been specifically engineered to target CD20-producing B cells with increased effectiveness. This potentially gives stronger and longer-lasting therapeutic effects than other anti-CD20 monoclonal antibody treatments (ofatumumab and ocrelizumab).
Recent comparisons suggest it is as effective as the other intravenous monoclonal antibody treatments. You can read more about ublituximab here.
How does its dosing schedule compare to other monoclonal antibodies?
Ublituximab is given twice a year after the initial dose and has an infusion time of one hour. This dosing schedule is less frequent than that of other monoclonal antibodies, ofatumumab and natalizumab, and the infusion time is shorter compared to ocrelizumab and alemtuzumab.
Additional information about ublituximab is available on MS Australia’s treatment information webpage.
What does this mean?
The listing of ublituximab provides an affordable option, and the dosing regimen may be a more convenient option for some people with relapsing remitting MS.
MS Australia supports equitable access to all proven treatment options to increase the opportunity for people with MS to access effective therapy. Given the varied nature of MS, no single medication is suitable for every Australian living with the disease.
MS Australia continues to advocate to improve the lives of people with MS and MS-related disorders. We remain committed to ensuring that all Australians living with MS and MS-related disorders can access high-quality affordable MS care.
